Wide spectrum of symptoms by parvovirus B19 infection and its relation to the virus strain

genetic diversity in The VP1 unique regionwhich is important for the neutralizing response to human parvovirus B19 was examined by themismatch detection method using Non-isotopic RNase Cleavage Assay (NIRCA D1TM) and directnucleotide sequencing. Twenty three B19 strains derived from various sources between 1986和1997were examined. Three electrophoresis patterns were observed by NIRCA D1TM . The nucleotidesequence showed that there were 14 nucleotide changes and 4 amino acid substitutions in comparisonwith Au strains employed as a standard strain. The nucleotide variability of all samples ranged from0.3% to 2.7% and the amino acid variability ranged from 1.0% to 3.0%.他们是分类intothree类型according to NIRCA D1TM数据D1. Type 1 and 3 had similar sequences，but the type 2 sequence was quite different.虽然有些nucleotide variations in thesame NIRCA D1TM数据D1 type， these were silent. However，there was no relationship between the clinical features and NIRCA D1TM types or betweenclinical features and nucleotide sequence. All samples obtained before 1987 were NIRCAtype 2. On the other hand，19 for 20 samples obtained after 1989 were NIRCA D1TM D1 type 1. The other sample obtained in 1992was type 3. The results suggest that The B19 strain of type2 disappeared by 1988 and changed toB19 strains such as type 1 and type 3 after 1988indicating a correlation between genome type and prevalence. NIRCA D1TM D1是一个convenient methodfor screening mutations due to its simplicity and quickness。

The genetic diversity in the VP1 unique region, which is important for the neutralizing response to human parvovirus B19 was examined by the mismatch detection method using Non-isotopic RNase Cleavage Assay (NIRCAィイD1TMィエD1) and direct nucleotide sequencing. Twenty three B19 strains derived from various sources between 1986 and 1997 were examined. Three electrophoresis patterns were observed by NIRCAィイD1TMィエD1. The nucleotide sequence showed that there were 14 nucleotide changes and 4 amino acid substitutions in comparison with Au strains employed as a standard strain. The nucleotide variability of all samples ranged from 0.3% to 2.7% and the amino acid variability ranged from 1.0% to 3.0%. They were classified into three types according to NIRCAィイD1TMィエD1. Type 1 and 3 had similar sequences, but the type 2 sequence was quite different. Although there were some nucleotide variations in the same NIRCAィイD1TMィエD1 type, these were silent. However, there was no relationship between the clinical features and NIRCAィイD1TMィエD1 types or between clinical features and nucleotide sequence. All samples obtained before 1987 were NIRCAィイD1TMィエD1 type 2. On the other hand, 19 for 20 samples obtained after 1989 were NIRCAィイD1TMィエD1 type 1. The other sample obtained in 1992 was type 3. The results suggest that the B19 strain of type2 disappeared by 1988 and changed to other B19 strains such as type 1 and type 3 after 1988, indicating a correlation between genome type and prevalence. NIRCAィイD1TMィエD1 is a convenient method for screening mutations due to its simplicity and quickness.